Viking Therapeutics (VKTX) Shares Gap Up to $13.30

Viking Therapeutics Inc (NASDAQ:VKTX)’s share price gapped up prior to trading on Friday . The stock had previously closed at $13.91, but opened at $13.30. Viking Therapeutics shares last traded at $14.19, with a volume of 140454 shares changing hands.

Several equities analysts recently weighed in on the stock. BidaskClub cut shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 3rd. William Blair reissued a “market perform” rating on shares of Viking Therapeutics in a research note on Monday, October 1st. HC Wainwright set a $31.00 target price on shares of Viking Therapeutics and gave the company a “buy” rating in a research note on Monday, October 1st. Raymond James set a $43.00 target price on shares of Viking Therapeutics and gave the company a “buy” rating in a research note on Wednesday, September 19th. Finally, Roth Capital raised their target price on shares of Viking Therapeutics from $13.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, September 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $28.17.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02). On average, equities research analysts forecast that Viking Therapeutics Inc will post -0.44 earnings per share for the current year.



In other Viking Therapeutics news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of Viking Therapeutics stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total transaction of $5,034,171.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.90% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in VKTX. Janney Montgomery Scott LLC bought a new position in Viking Therapeutics during the second quarter worth $114,000. Strs Ohio bought a new position in Viking Therapeutics during the second quarter worth $120,000. Cubist Systematic Strategies LLC bought a new position in Viking Therapeutics during the second quarter worth $129,000. State Board of Administration of Florida Retirement System bought a new position in Viking Therapeutics during the second quarter worth $144,000. Finally, Metropolitan Life Insurance Co. NY bought a new position in Viking Therapeutics during the second quarter worth $145,000. 52.65% of the stock is owned by hedge funds and other institutional investors.

About Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

See Also: Relative Strength Index

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply